Correction (DOI:10.1016/j.cgh.2006.06.010);Dermatologic Disorders Associated With Chronic Hepatitis C: Effect of Interferon Therapy

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 2, 2007, Pages 142-151

  Berk, David R ^a   Mallory, Susan Bayliss ^a   Keeffe, Emmet B ^b   Ahmed, Aijaz ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANESTHETIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ERYTHROPOIETIN; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; INTERFERON; PEGINTERFERON; RETINOIC ACID; RETINOID; RIBAVIRIN;

ALOPECIA; APHERESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MEGADOSE; ERYTHEMA; FIXED DRUG ERUPTION; HEPATITIS C; HERPES ZOSTER; HUMAN; HYPERPIGMENTATION; INJECTION SITE REACTION; LICHEN PLANUS; LICHENOID ERUPTION; LOW DRUG DOSE; MACULOPAPULAR RASH; MONOTHERAPY; PHLEBOTOMY; PLASMAPHERESIS; PORPHYRIA CUTANEA TARDA; PRURIGO; PRURITUS; PUVA; REVIEW; ROSACEA; SEBORRHEIC DERMATITIS; SKIN DISEASE; SKIN INDURATION;

EID: 33846813689     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.03.007     Document Type: Erratum

References (171)

1. Mayo M.J. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci 325 (2003) 135-148
2. Medina J., Garcia-Buey L., and Moreno-Otero R. Hepatitis C virus-related extrahepatic disease: aetiopathogenesis and management. Aliment Pharmacol Ther 20 (2004) 129-141
3. Sene D., Ghillani-Dalbin P., Thibault V., et al. Long-term course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol 31 (2004) 2199-2206
4. Bonkovsky H.L., and Mehta S. Hepatitis C: a review and update. J Am Acad Dermatol 44 (2001) 159-182
5. Hadziyannis S.J. Skin diseases associated with hepatitis C virus infection. J Eur Acad Dermatol Venereol 10 (1998) 12-21
6. Doutre M.S. Hepatitis C virus-related skin diseases. Arch Dermatol 135 (1999) 1401-1403
7. Jackson J.M. Hepatitis C and the skin. Dermatol Clin 20 (2002) 449-458
8. Fernandez I., Castellano G., de Salamanca R.E., et al. Porphyria cutanea tarda as a predictor of poor response to interferon alfa therapy in chronic hepatitis C. Scand J Gastroenterol 38 (2003) 314-319
9. Edwards L. The interferons. Dermatol Clin 19 (2001) 139-146 ix
10. Wilson L.E., Widman D., Dikman S.H., et al. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 32 (2002) 163-173
11. Rockstroh J.K., Spengler U., Sudhop T., et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 91 (1996) 2563-2568
12. Magrin S., Craxi A., Fabiano C., et al. Hepatitis C viremia in chronic liver disease: relationship to interferon-alpha or corticosteroid treatment. Hepatology 19 (1994) 273-279
13. Fong T.L., Valinluck B., Govindarajan S., et al. Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. Gastroenterology 107 (1994) 196-199
14. Ramos-Casals M., Mana J., Nardi N., et al. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. Medicine (Baltimore) 84 (2005) 69-80
15. Roenigk Jr. H.H., Auerbach R., Maibach H.I., et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 19 (1988) 145-156
16. Camuto P., Shupack J., Orbuch P., et al. Long-term effects of etretinate on the liver in psoriasis. Am J Surg Pathol 11 (1987) 30-37
17. Ramos-Casals M., Trejo O., Garcia-Carrasco M., et al. Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection. Rheumatology (Oxford) 42 (2003) 818-828
18. Hadziyannis S.J., and Vassilopoulos D. Complex management issues: management of HCV in the atypical patient. Baillieres Best Pract Res Clin Gastroenterol 14 (2000) 277-291
19. Wasley A., and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20 (2000) 1-16
20. Lodi G., Giuliani M., Majorana A., et al. Lichen planus and hepatitis C virus: a multicentre study of patients with oral lesions and a systematic review. Br J Dermatol 151 (2004) 1172-1181
21. Fargion S., and Fracanzani A.L. Prevalence of hepatitis C virus infection in porphyria cutanea tarda. J Hepatol 39 (2003) 635-638
22. Gisbert J.P., Garcia-Buey L., Pajares J.M., et al. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39 (2003) 620-627
23. Okanoue T., Sakamoto S., Itoh Y., et al. Side effects of high-dose interferon therapy for chronic hepatitis C. J Hepatol 25 (1996) 283-291
24. Sookoian S., Neglia V., Castano G., et al. High prevalence of cutaneous reactions to interferon alfa plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol 135 (1999) 1000-1001
25. Dalekos G.N., Christodoulou D., Kistis K.G., et al. A prospective evaluation of dermatological side effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol 10 (1998) 933-939
26. Manjon-Haces J.A., Vazquez-Lopez F., Gomez-Diez S., et al. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus. Acta Derm Venereol 81 (2001) 223
27. Kerl K., Negro F., and Lubbe J. Cutaneous side effects of treatment of chronic hepatitis C by interferon alfa and ribavirin. Br J Dermatol 149 (2003) 656
28. Cottoni F., Bolognini S., Deplano A., et al. Skin reaction in antiviral therapy for chronic hepatitis C: a role for polyethylene glycol interferon?. Acta Derm Venereol 84 (2004) 120-123
29. Guillot B., Blazquez L., Bessis D., et al. A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma. Dermatology 208 (2004) 49-54
30. Lubbe J., Kerl K., Negro F., et al. Clinical and immunological features of hepatitis C treatment-associated dermatitis in 36 prospective cases. Br J Dermatol 153 (2005) 1088-1090
31. Cacoub P., Ratziu V., Myers R.P., et al. Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C. J Hepatol 36 (2002) 812-818
32. Zignego A.L., Ferri C., Monti M., et al. Hepatitis C virus as a lymphotropic agent: evidence and pathogenetic implications. Clin Exp Rheumatol 13 Suppl 13 (1995) S33-S37
33. Pawlotsky J.M., Ben Yahia M., Andre C., et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 19 (1994) 841-848
34. Ferri C., Sebastiani M., Giuggioli D., et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 33 (2004) 355-374
35. Crowson A.N., Nuovo G., Ferri C., et al. The dermatopathologic manifestations of hepatitis C infection: a clinical, histological, and molecular assessment of 35 cases. Hum Pathol 34 (2003) 573-579
36. Agnello V., Chung R.T., and Kaplan L.M. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 327 (1992) 1490-1495
37. La Civita L., Zignego A.L., Bernacchi E., et al. Hepatitis C virus infection and cutaneous vasculitis in mixed cryoglobulinemia. Mayo Clin Proc 71 (1996) 109-110
38. Lazaro P., Olalquiaga J., Bartolome J., et al. Detection of hepatitis C virus RNA and core protein in keratinocytes from patients with cutaneous lichen planus and chronic hepatitis C. J Invest Dermatol 119 (2002) 798-803
39. Podanyi B., Kiss A., Kaposi Novak P., et al. Hepatitis C virus RNA in the skin eruption from patients with prurigo and chronic hepatitis C. Orv Hetil 145 (2004) 2371-2374
40. Ujiie H., Shimizu T., and Shimizu H. Generalized pustular psoriasis and hepatitis C virus infection. Acta Virol 48 (2004) 63-64
41. Cacoub P., Renou C., Rosenthal E., et al. Extrahepatic manifestations associated with hepatitis C virus infection: a prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 79 (2000) 47-56
42. Paoletti V., Mammarella A., Basili S., et al. Prevalence and clinical features of skin diseases in chronic HCV infection: a prospective study in 96 patients. Panminerva Med 44 (2002) 349-352
43. Kanazawa K., Yaoita H., Tsuda F., et al. Association of prurigo with hepatitis C virus infection. Arch Dermatol 131 (1995) 852-853
44. el Darouti M., and Abu el Ela M. Necrolytic acral erythema: a cutaneous marker of viral hepatitis C. Int J Dermatol 35 (1996) 252-256
45. Soufir N., Descamps V., Crickx B., et al. Hepatitis C virus infection in cutaneous polyarteritis nodosa: a retrospective study of 16 cases. Arch Dermatol 135 (1999) 1001-1002
46. Ferri C., Zignego A.L., Giuggioli D., et al. HCV and cryoglobulinemic vasculitis. Cleve Clin J Med 69 Suppl 2 (2002) SII20-SII23
47. Ferri C., Giuggioli D., Cazzato M., et al. HCV-related cryoglobulinemic vasculitis: an update on its etiopathogenesis and therapeutic strategies. Clin Exp Rheumatol 21 (2003) S78-S84
48. Ferri C., Zignego A.L., and Pileri S.A. Cryoglobulins. J Clin Pathol 55 (2002) 4-13
49. Donada C., Crucitti A., Donadon V., et al. Systemic manifestations and liver disease in patients with chronic hepatitis C and type II or III mixed cryoglobulinaemia. J Viral Hepat 5 (1998) 179-185
50. Frangeul L., Musset L., Cresta P., et al. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 25 (1996) 427-432
51. Calleja J.L., Albillos A., Moreno-Otero R., et al. Sustained response to interferon-alpha or to interferon-alpha plus ribavirin in hepatitis C virus-associated symptomatic mixed cryoglobulinaemia. Aliment Pharmacol Ther 13 (1999) 1179-1186
52. Dupin N., Chosidow O., Lunel F., et al. Essential mixed cryoglobulinemia: a comparative study of dermatologic manifestations in patients infected or noninfected with hepatitis C virus. Arch Dermatol 131 (1995) 1124-1127
53. Della Rossa A., Tavoni A., Baldini C., et al. Treatment of chronic hepatitis C infection with cryoglobulinemia. Curr Opin Rheumatol 14 (2002) 231-237
54. Zuckerman E., Keren D., Slobodin G., et al. Treatment of refractory, symptomatic, hepatitis C virus-related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 27 (2000) 2172-2178
55. Boonyapisit K., and Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 25 (2002) 909-913
56. Mazzaro C., Franzin F., Tulissi P., et al. Regression of monoclonal B-cell expansion in patients affected by mixed cryoglobulinemia responsive to alpha-interferon therapy. Cancer 77 (1996) 2604-2613
57. Giannelli F., Moscarella S., Giannini C., et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 102 (2003) 1196-1201
58. Ferri C., Marzo E., Longombardo G., et al. Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 81 (1993) 1132-1136
59. Casato M., Agnello V., Pucillo L.P., et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 90 (1997) 3865-3873
60. Misiani R., Bellavita P., Fenili D., et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330 (1994) 751-756
61. Mazzaro C., Pozzato G., Moretti M., et al. Long-term effects of alpha-interferon therapy for type II mixed cryoglobulinemia. Haematologica 79 (1994) 342-349
62. Polzien F., Schott P., Mihm S., et al. Interferon-alpha treatment of hepatitis C virus-associated mixed cryoglobulinemia. J Hepatol 27 (1997) 63-71
63. Lamprecht P., Moosig F., Gause A., et al. Immunological and clinical follow-up of hepatitis C virus-associated cryoglobulinaemic vasculitis. Ann Rheum Dis 60 (2001) 385-390
64. Beuthien W., Mellinghoff H.U., and Kempis J.V. Vasculitic complications of interferon-alpha treatment for chronic hepatitis C virus infection: case report and review of the literature. Clin Rheumatol 24 (2005) 507-515
65. Levine J.W., Gota C., Fessler B.J., et al. Persistent cryoglobulinemic vasculitis following successful treatment of hepatitis C virus. J Rheumatol 32 (2005) 1164-1167
66. Batisse D., Karmochkine M., Jacquot C., et al. Sustained exacerbation of cryoglobulinaemia-related vasculitis following treatment of hepatitis C with peginterferon alfa. Eur J Gastroenterol Hepatol 16 (2004) 701-703
67. Naarendorp M., Kallemuchikkal U., Nuovo G.J., et al. Long-term efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 28 (2001) 2466-2473
68. Casato M., Lagana B., Antonelli G., et al. Long-term results of therapy with interferon-alpha for type II essential mixed cryoglobulinemia. Blood 78 (1991) 3142-3147
69. Mazzaro C., Zorat F., Caizzi M., et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 42 (2005) 632-638
70. Donada C., Crucitti A., Donadon V., et al. Interferon and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 92 (1998) 2983-2984
71. Mazzaro C., Zorat F., Comar C., et al. Interferon plus ribavirin in patients with hepatitis C virus-positive mixed cryoglobulinemia resistant to interferon. J Rheumatol 30 (2003) 1775-1781
72. Cacoub P., Lidove O., Maisonobe T., et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 46 (2002) 3317-3326
73. Cacoub P., Saadoun D., Limal N., et al. PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 52 (2005) 911-915
74. Durand J.M., Cacoub P., Lunel-Fabiani F., et al. Ribavirin in hepatitis C-related cryoglobulinemia. J Rheumatol 25 (1998) 1115-1117
75. Bleasel N.R., and Varigos G.A. Porphyria cutanea tarda. Aust J Dermatol 41 (2000) 197-208
76. Sarkany R.P. The management of porphyria cutanea tarda. Clin Exp Dermatol 26 (2001) 225-232
77. Sams H., Kiripolsky M.G., Bhat L., et al. Porphyria cutanea tarda, hepatitis C, alcoholism, and hemochromatosis: a case report and review of the literature. Cutis 73 (2004) 188-190
78. Kordac V., and Semradova M. Treatment of porphyria cutanea tarda with chloroquine. Br J Dermatol 90 (1974) 95-100
79. Siegel L.B., and Eber B.B. Porphyria cutanea tarda remission. Ann Intern Med 121 (1994) 308-309
80. Dohmen K., Nakamura H., Morita C., et al. Chronic hepatitis C associated with porphyria cutanea tarda. Nippon Shokakibyo Gakkai Zasshi 91 (1994) 345-349
81. Grasset D., Nougue J., Seigneuric C., et al. Porphyria cutanea tarda and chronic hepatitis C: course after interferon therapy. Gastroenterol Clin Biol 18 (1994) 1148-1149
82. Takikawa H., Yamazaki R., Shoji S., et al. Normalization of urinary porphyrin level and disappearance of skin lesions after successful interferon therapy in a case of chronic hepatitis C complicated with porphyria cutanea tarda. J Hepatol 22 (1995) 249-250
83. About I., Cassagnaveres E., and Capdeville J. Familial porphyria cutanea tarda disclosed by chronic hepatitis C: apropos of a case. Rev Med Interne 17 (1996) 1020-1024
84. Okano J., Horie Y., Kawasaki H., et al. Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C. Hepatogastroenterology 44 (1997) 525-528
85. Sheikh M.Y., Wright R.A., and Burruss J.B. Dramatic resolution of skin lesions associated with porphyria cutanea tarda after interferon-alpha therapy in a case of chronic hepatitis C. Dig Dis Sci 43 (1998) 529-533
86. Furuta M., Kaito M., Gabazza E., et al. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels. J Gastroenterol 35 (2000) 60-62
87. Albalate M., Farinas M.C., Octavio J.G., et al. Development of porphyria cutanea tarda in a hemodialysis patient after reactivation of hepatitis C virus infection. Nephron 88 (2001) 170-173
88. Jessner W., Der-Petrossian M., Christiansen L., et al. Porphyria cutanea tarda during interferon/ribavirin therapy for chronic hepatitis C. Hepatology 36 (2002) 1301-1302
89. Bauza A., Espana A., and Lloret P. Porphyria cutanea tarda, dermatomyositis and non-Hodgkin lymphoma in virus C infection. Eur J Dermatol 13 (2003) 302-304
90. Thevenot T., Bachmeyer C., Hammi R., et al. Occurrence of porphyria cutanea tarda during peginterferon/ribavirin therapy for chronic viral hepatitis C. J Hepatol 42 (2005) 607-608
91. Howaizi M. Pegylated interferon-induced eyelid and eyebrow trichomegaly during chronic hepatitis C. J Gastroenterol Hepatol 20 (2005) 1945-1946
92. Sacchi S., Kantarjian H., O'Brien S., et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 13 (1995) 2401-2407
93. Hacker S.M., Berkwitz M., and Cody R. Porphyria cutanea tarda in a patient with hairy cell leukemia. Cutis 51 (1993) 251-252
94. Lim H.W., Pereira A., Sassa S., et al. Early-stage HIV infection and hepatitis C virus infection are associated with elevated serum porphyrin levels. J Am Acad Dermatol 39 (1998) 956-959
95. Nomura N., Zolla-Pazner S., Simberkoff M., et al. Abnormal serum porphyrin levels in patients with the acquired immunodeficiency syndrome with or without hepatitis C virus infection. Arch Dermatol 132 (1996) 906-910
96. O'Connor W.J., Murphy G.M., Darby C., et al. Porphyrin abnormalities in acquired immunodeficiency syndrome. Arch Dermatol 132 (1996) 1443-1447
97. Cribier B., Rey D., Uhl G., et al. Abnormal urinary coproporphyrin levels in patients infected by hepatitis C virus with or without human immunodeficiency virus: a study of 177 patients. Arch Dermatol 132 (1996) 1448-1452
98. O'Reilly F.M., Darby C., Fogarty J., et al. Porphyrin metabolism in hepatitis C infection. Photodermatol Photoimmunol Photomed 12 (1996) 31-33
99. Hussain I., Hepburn N.C., Jones A., et al. The association of hepatitis C viral infection with porphyria cutanea tarda in the Lothian region of Scotland. Clin Exp Dermatol 21 (1996) 283-285
100. Gibson P.R., Grant J., Cronin V., et al. Effect of hepatobiliary disease, chronic hepatitis C and hepatitis B virus infections and interferon-alpha on porphyrin profiles in plasma, urine and faeces. J Gastroenterol Hepatol 15 (2000) 192-201
101. Rich J.D., Mylonakis E., Nossa R., et al. Highly active antiretroviral therapy leading to resolution of porphyria cutanea tarda in a patient with AIDS and hepatitis C. Dig Dis Sci 44 (1999) 1034-1037
102. Goldblum O.M. Lichen planus. Skinmed 1 (2002) 52-53
103. Eisen D. The clinical features, malignant potential, and systemic associations of oral lichen planus: a study of 723 patients. J Am Acad Dermatol 46 (2002) 207-214
104. Eisen D. The clinical manifestations and treatment of oral lichen planus. Dermatol Clin 21 (2003) 79-89
105. Heintges T., Frieling T., Goerz G., et al. Exacerbation of lichen planus but not of acute intermittent hepatic porphyria during interferon therapy in a patient with chronic hepatitis C. J Hepatol 21 (1994) 1152-1153
106. Doutre M.S., Beylot C., Couzigou P., et al. Lichen planus and virus C hepatitis: disappearance of the lichen under interferon alfa therapy. Dermatology 184 (1992) 229
107. Agner T., Fogh H., and Weismann K. The relation between lichen planus and hepatitis C: a case report. Acta Derm Venereol 72 (1992) 380
108. Strumia R., Venturini D., Boccia S., et al. UVA and interferon-alfa therapy in a patient with lichen planus and chronic hepatitis C. Int J Dermatol 32 (1993) 386
109. Protzer U., Ochsendorf F.R., Leopolder-Ochsendorf A., et al. Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 104 (1993) 903-905
110. Sassigneux P., Michel P., Joly P., et al. Eruptive mucocutaneous lichen planus during treatment of chronic hepatitis C with interferon alpha. Gastroenterol Clin Biol 17 (1993) 764
111. d'Agay-Abensour L., Benamouzig R., de Belilovsky C., et al. Lichen planus during chronic hepatitis C treated with interferon alpha. Gastroenterol Clin Biol 16 (1992) 610-611
112. Perreard M., Constant T., Monges D., et al. Mucocutaneous lichen planus induced by a second treatment with high-dose interferon-alpha in a patient with chronic viral hepatitis C. Gastroenterol Clin Biol 18 (1994) 1051
113. Papini M., Bruni P.L., Bettacchi A., et al. Sudden onset of oral ulcerative lichen in a patient with chronic hepatitis C on treatment with alfa-interferon. Int J Dermatol 33 (1994) 221-222
114. Frider B., Sookoian S., Castano G., et al. Lichen planus, chronic hepatitis C and interferon. Hepatology 21 (1995) 1764-1765
115. Revenga Arranz F., de Argila Fernandez-Duran D., Rivera Diaz R., et al. Lichen planus and hepatitis C virus infection: study of 6 cases. Rev Clin Esp 195 (1995) 550-552
116. Fornaciari G., Albertini G., Maccari S., et al. Lichen planus during lymphoblastoid interferon treatment for chronic active hepatitis C. J Clin Gastroenterol 20 (1995) 346-347
117. Nunez M., Miralles E.S., de las Heras M.E., et al. Appearance of oral erosive lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. J Dermatol 22 (1995) 461-462
118. Barreca T., Corsini G., Franceschini R., et al. Lichen planus induced by interferon-alpha 2a therapy for chronic active hepatitis C. Eur J Gastroenterol Hepatol 7 (1995) 367-368
119. Hyrailles V., Peyron N., Blanc P., et al. Lichen planus and hepatitis C virus: apropos of 5 new cases. Gastroenterol Clin Biol 19 (1995) 833-836
120. Doutre M.S., Couzigou P., Beylot-Barry M., et al. Lichen planus and hepatitis C: heterogeneity in the course of 6 cases treated with interferon alpha. Gastroenterol Clin Biol 20 (1996) 709-710
121. Fattovich G., Giustina G., Favarato S., et al. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 24 (1996) 38-47
122. Nagao Y., Sata M., Ide T., et al. Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest 26 (1996) 1171-1174
123. Nagao Y., Sata M., Suzuki H., et al. Histological improvement of oral lichen planus in patients with chronic hepatitis C treated with interferon. Gastroenterology 117 (1999) 283-284
124. Lapidoth M., Arber N., Ben-Amitai D., et al. Successful interferon treatment for lichen planus associated with chronic active hepatitis due to hepatitis C virus infection. Acta Derm Venereol 77 (1997) 171-172
125. Schlesinger T.E., Camisa C., Gay J.D., et al. Oral erosive lichen planus with epidermolytic hyperkeratosis during interferon alfa-2b therapy for chronic hepatitis C virus infection. J Am Acad Dermatol 36 (1997) 1023-1025
126. Varela P., Areias J., Mota F., et al. Oral lichen planus induced by interferon-alpha-N1 in a patient with hepatitis C. Int J Dermatol 39 (2000) 239-240
127. Sugiyama T., Shimizu M., Ohnishi H., et al. Clinical evaluation in oral lichen planus with chronic hepatitis C: the role of interferon treatment. Nippon Shokakibyo Gakkai Zasshi 97 (2000) 568-574
128. Guijarro Guijarro B., Lopez Sanchez A.F., et al. Presence of lichen planus during a course of interferon alpha-2a therapy for a viral chronic C hepatitis. Med Oral 6 (2001) 358-363
129. Harden D., Skelton H., and Smith K.J. Lichen planus associated with hepatitis C virus: no viral transcripts are found in the lichen planus, and effective therapy for hepatitis C virus does not clear lichen planus. J Am Acad Dermatol 49 (2003) 847-852
130. Pinto J.M., Marques M.S., and Correia T.E. Lichen planus and leukocytoclastic vasculitis induced by interferon alpha-2b in a subject with HCV-related chronic active hepatitis. J Eur Acad Dermatol Venereol 17 (2003) 193-195
131. Nagao Y., Kawaguchi T., Ide T., et al. Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C. Int J Mol Med 15 (2005) 237-241
132. Hildebrand A., Kolde G., Luger T.A., et al. Successful treatment of generalized lichen planus with recombinant interferon alfa-2b. J Am Acad Dermatol 33 (1995) 880-883
133. Engelmann L., and Kunze J. Successful treatment of extensive lichen planus and ulcerous oral lesions with recombinant interferon-gamma. [abstract]. Arch Dermatol Res (1992) 284
134. Pedersen A. IFN-alpha cream in the treatment of oral lichen planus. Oral Dis 4 (1998) 155-156
135. Kutting B., Bohm M., Luger T.A., et al. Oropharyngeal lichen planus associated with interferon-alpha treatment for mycosis fungoides: a rare side effect in the therapy of cutaneous lymphomas. Br J Dermatol 137 (1997) 836-837
136. Rodrigues B., Oliveira M., and Inock A. Lichen plan induit par l'interferon alpha 2b chez un malade avec un myeloma a IgG. Nouv Dermatol 8 (1989) 29-31
137. Herrera Saval A., and Camacho Martinez F. Lichen planus induced by interferon-alpha 2B therapy in a patient with cutaneous malignant melanoma. Acta Derm Venereol 79 (1999) 395
138. Willems M., Munte K., Vrolijk J.M., et al. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Br J Dermatol 149 (2003) 390-394
139. Jensen S.L., and Holmes R. Rosacea fulminans associated with pegylated interferon alpha-2B and ribavirin therapy. J Drugs Dermatol 2 (2003) 554-556
140. Sidhu-Malik N.K., and Kaplan A.L. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection. J Drugs Dermatol 2 (2003) 570-573
141. Cribier B.J., Santinelli F., Schmitt C., et al. Chronic urticaria is not significantly associated with hepatitis C or hepatitis G infection: a case-control study. Arch Dermatol 135 (1999) 1335-1339
142. Davis G.L., Esteban-Mur R., Rustgi V., et al., International Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 339 (1998) 1493-1499
143. McHutchison J.G., Gordon S.C., Schiff E.R., et al., Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339 (1998) 1485-1492
144. Chouela E., Abeldano A., Panetta J., et al. Hepatitis C virus antibody (anti-HCV): prevalence in psoriasis. Int J Dermatol 35 (1996) 797-799
145. Kanazawa K., Aikawa T., Tsuda F., et al. Hepatitis C virus infection in patients with psoriasis. Arch Dermatol 132 (1996) 1391-1392
146. Yamamoto T., Katayama I., and Nishioka K. Psoriasis and hepatitis C virus. Acta Derm Venereol 75 (1995) 482-483
147. Burrows N.P., Norris P.G., Alexander G., et al. Chronic hepatitis C infection and psoriasis. Dermatology 190 (1995) 173
148. Taglione E., Vatteroni M.L., Martini P., et al. Hepatitis C virus infection: prevalence in psoriasis and psoriatic arthritis. J Rheumatol 26 (1999) 370-372
149. Palazzi C., Olivieri I., D'Amico E., et al. Hepatitis C virus infection in psoriatic arthritis. Arthritis Rheum 53 (2005) 223-225
150. Lombardini F., Taglione E., Riente L., et al. Psoriatic arthritis with spinal involvement in a patient receiving alpha-interferon for chronic hepatitis C. Scand J Rheumatol 26 (1997) 58-60
151. Pellicano R., Puiatti P., Palmas P., et al. The exacerbation of psoriasis during treatment with alfa interferon. Recenti Prog Med 88 (1997) 423
152. Piqueras Alcol B., de Diego Lorenzo A., Perez Roldan F., et al. Interferon-alpha and development of psoriatic arthropathy. An Med Int 13 (1996) 512-513
153. Wolfer L.U., Goerdt S., Schroder K., et al. Interferon-alpha-induced psoriasis vulgaris. Hautarzt 47 (1996) 124-128
154. Cervoni J.P., Serfaty L., Picard O., et al. The treatment of hepatitis B and C with interferon-alpha can induce or aggravate psoriasis. Gastroenterol Clin Biol 19 (1995) 324-325
155. Makino Y., Tanaka H., Nakamura K., et al. Arthritis in a patient with psoriasis after interferon-alpha therapy for chronic hepatitis C. J Rheumatol 21 (1994) 1771-1772
156. Taylor C., Burns D.A., and Wiselka M.J. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J 76 (2000) 365-367
157. Erkek E., Karaduman A., Akcan Y., et al. Psoriasis associated with HCV and exacerbated by interferon alpha: complete clearance with acitretin during interferon alpha treatment for chronic active hepatitis. Dermatology 201 (2000) 179-181
158. Downs A.M., and Dunnill M.G. Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol 25 (2000) 351-352
159. Kartal E.D., Colak H., Ozgunes I., et al. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 51 (2005) 167-169
160. Bonnet F., Dubuc J., Morlat P., et al. Sarcoidosis and comorbidity: retrospective study of 32 cases. Rev Med Intern 22 (2001) 619-623
161. Bresnitz E.A., and Strom B.L. Epidemiology of sarcoidosis. Epidemiol Rev 5 (1983) 124-156
162. Fiorani C., Sacchi S., Bonacorsi G., et al. Systemic sarcoidosis associated with interferon-alpha treatment for chronic myelogenous leukemia. Haematologica 85 (2000) 1006-1007
163. Carson C.W., Conn D.L., Czaja A.J., et al. Frequency and significance of antibodies to hepatitis C virus in polyarteritis nodosa. J Rheumatol 20 (1993) 304-309
164. Dohmen K., Miyamoto Y., Irie K., et al. Manifestation of cutaneous polyarteritis nodosa during interferon therapy for chronic hepatitis C associated with primary biliary cirrhosis. J Gastroenterol 35 (2000) 789-793
165. Dega H., Frances C., Dupin N., et al., The MULTIVIRC Unit. Pruritis and the hepatitis C virus. Ann Dermatol Venereol 125 (1998) 9-12
166. Neri S., Raciti C., D'Angelo G., et al. Hyde's prurigo nodularis and chronic HCV hepatitis. J Hepatol 28 (1998) 161-164
167. Noh G., and Lee K.Y. Successful interferon alpha therapy in atopic dermatitis of Besnier's prurigo pattern with normal serum IgE and blood eosinophil fraction: a randomized case-controlled study. Cytokine 13 (2001) 124-128
168. Abdallah M.A., Hull C., and Horn T.D. Necrolytic acral erythema: a patient from the United States successfully treated with oral zinc. Arch Dermatol 141 (2005) 85-87
169. Hivnor C.M., Yan A.C., Junkins-Hopkins J.M., et al. Necrolytic acral erythema: response to combination therapy with interferon and ribavirin. J Am Acad Dermatol 50 (2004) S121-S124
170. Khanna V.J., Shieh S., Benjamin J., et al. Necrolytic acral erythema associated with hepatitis C: effective treatment with interferon alfa and zinc. Arch Dermatol 136 (2000) 755-757
171. Abdallah M.A., Ghozzi M.Y., Monib H.A., et al. Histological study of necrolytic acral erythema. J Ark Med Soc 100 (2004) 354-355